Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MacroGenics Inc MGNX

Healthcare Biotechnology
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor... see more

Recent & Breaking News (NDAQ:MGNX)

Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for Investors - Contact Levi & Korsinsky

Accesswire July 31, 2024

NASDAQ:MGNX: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against MacroGenics, Inc.

Business Wire July 31, 2024

Levi & Korsinsky Reminds MacroGenics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX

Accesswire July 31, 2024

MGNX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Newsfile July 31, 2024

MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Accesswire July 31, 2024

MGNX INVESTOR ALERT: MacroGenics Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

Newsfile July 31, 2024

Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX

Accesswire July 31, 2024

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics

Newsfile July 31, 2024

Investors who Lost Money on MacroGenics, Inc.(MGNX) Should Contact Levi & Korsinsky About Pending Class Action - MGNX

Accesswire July 31, 2024

MacroGenics (MGNX) Faces Class Action After Revealing Investigation of Patient Deaths in TAMARACK Study of Vobra Duo - Hagens Berman

Accesswire July 31, 2024

MGNX INVESTOR NOTICE: MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Accesswire July 31, 2024

Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc. (MGNX) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire July 31, 2024

The Schall Law Firm Is Investigating MacroGenics Inc And Encourages Its Shareholders To Reach Out To Them

Accesswire July 31, 2024

Contact Levi & Korsinsky by September 24, 2024 Deadline to Join Class Action Against MacroGenics, Inc.(MGNX)

Accesswire July 30, 2024

MACROGENICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against MacroGenics, Inc. - MGNX

Business Wire July 30, 2024

MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGNX

Accesswire July 30, 2024

Lost Money on MacroGenics, Inc.(MGNX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Accesswire July 30, 2024

ROSEN, A LEADING NATIONAL FIRM, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MGNX

Newsfile July 30, 2024

MacroGenics Provides Vobramitamab Duocarmazine Update

GlobeNewswire July 30, 2024

MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte

GlobeNewswire July 30, 2024